Literature DB >> 32548160

Extensive multifocal and pleomorphic pulmonary lesions in Waldenström macroglobulinemia: A case report.

De-Feng Zhao1, Hao-Yong Ning2, Jian Cen3, Yi Liu3, Li-Ren Qian3, Zhi-Hai Han4, Jian-Liang Shen5.   

Abstract

BACKGROUND: Waldenström macroglobulinemia (WM) is a type of small lymphocytic lymphoma that mainly affects the bone marrow, spleen, and lymph nodes. A subset of patients with WM demonstrates extramedullary involvement (4.4%), and the most frequent extramedullary disease site involved is the lungs (30%). CASE
SUMMARY: A 60-year-old male patient who experienced intermittent breath-holding for 6 mo was admitted on August 14, 2017. Chest computed tomography indicated multiple pulmonary cavities in the upper lobes of both lungs, with pulmonary consolidation, ground-glass opacities, patchy infiltrates, fibrous bands, large bullae, and enlarged lymph nodes in the mediastinum. The patient was a heavy smoker (20 cigarettes/d for 40 years). Diagnostic fiberoptic bronchoscopy revealed normal findings. Serological examination revealed a remarkable increase in serum immunoglobulin M levels (30.24 g/L; normal: 0.4-2.30 g/L). A computed tomography-guided percutaneous pulmonary biopsy was performed in the left lower lobe of the lung with pulmonary consolidation and indicated that the alveolar structure disappeared and that a large amount of amyloid-like deposition was present along with the infiltration of very few lymphocytes and plasma cells. The patient was treated with the combined treatment of dexamethasone + rituximab + lenalidomide over four courses. Serum immunoglobulin M did not normalize, and he received ibrutinib + dexamethasone.
CONCLUSION: This patient with WM and lung amyloidosis had a wide range of pulmonary lesions and a variety of morphological features, which was a rare case. Yet, some changes might be ascribed to heavy smoking. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Amyloidosis; Case report; Computed tomography; Lung; Waldenström macroglobulinemia

Year:  2020        PMID: 32548160      PMCID: PMC7281034          DOI: 10.12998/wjcc.v8.i11.2305

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  9 in total

1.  Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.

Authors:  Efstathios Kastritis; Maria Gavriatopoulou; Marie-Christine Kyrtsonis; Maria Roussou; Evdoxia Hadjiharissi; Argyris Symeonidis; Panagiotis Repoussis; Evridiki Michalis; Sosana Delimpasi; Konstantinos Tsatalas; Panagiotis Tsirigotis; Amalia Vassou; Elina Vervessou; Eirini Katodritou; Dimitra Gika; Evangelos Terpos; Meletios A Dimopoulos
Journal:  Blood       Date:  2015-09-10       Impact factor: 22.113

2.  Guidelines on the diagnosis and investigation of AL amyloidosis.

Authors:  Julian D Gillmore; Ashutosh Wechalekar; Jenny Bird; Jamie Cavenagh; Stephen Hawkins; Majid Kazmi; Helen J Lachmann; Philip N Hawkins; Guy Pratt
Journal:  Br J Haematol       Date:  2014-10-14       Impact factor: 6.998

3.  Interstitial pulmonary amyloidosis with Waldenström's macroglobulinemia.

Authors:  Kayoko Okamura; Junji Takiguchi; Hirokazu Sakamoto; Nobutaka Inoue
Journal:  Intern Med       Date:  2015       Impact factor: 1.271

4.  Extramedullary Waldenström macroglobulinemia.

Authors:  Ranjit Banwait; Yosra Aljawai; Joseph Cappuccio; Serena McDiarmid; Elizabeth A Morgan; Houry Leblebjian; Aldo M Roccaro; Jacob Laubach; Jorge J Castillo; Claudia Paba-Prada; Steven Treon; Robert Redd; Edie Weller; Irene M Ghobrial
Journal:  Am J Hematol       Date:  2014-11-19       Impact factor: 10.047

Review 5.  Primary lung involvement in Waldenström's macroglobulinaemia: report of two cases and review of the literature.

Authors:  M C Kyrtsonis; M K Angelopoulou; F N Kontopidou; M P Siakantaris; M N Dimopoulou; F Mitropoulos; A Kalovidouris; G A Vaiopoulos; G A Pangalis
Journal:  Acta Haematol       Date:  2001       Impact factor: 2.195

6.  New Therapeutic Approaches for Waldenstrom Macroglobulinemia.

Authors:  Jennifer Stedman; Aldo Roccaro; Xavier Leleu; Irene M Ghobrial
Journal:  Drugs Future       Date:  2010-01       Impact factor: 0.148

Review 7.  Amyloidosis of the Lung.

Authors:  Andras Khoor; Thomas V Colby
Journal:  Arch Pathol Lab Med       Date:  2017-02       Impact factor: 5.534

8.  Waldenström's macroglobulinemia-associated renal amyloidosis presenting as a solitary lung mass.

Authors:  Yuan-You Chung; Chuan-Cheng Wang; Kuan-Ju Lai; Chia-Chu Chang
Journal:  Ren Fail       Date:  2012-09-06       Impact factor: 2.606

9.  Guidelines on the diagnosis and management of Waldenström macroglobulinaemia.

Authors:  Roger G Owen; Guy Pratt; Rebecca L Auer; Rita Flatley; Charalampia Kyriakou; Michael P Lunn; Francis Matthey; Helen McCarthy; Feargal P McNicholl; Saad M Rassam; Simon D Wagner; Matthew Streetly; Shirley D'Sa
Journal:  Br J Haematol       Date:  2014-02-15       Impact factor: 6.998

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.